期刊文献+

造影增强超声对孤立性甲状腺结节的诊断价值 被引量:9

下载PDF
导出
摘要 目的利用造影增强超声评价孤立性甲状腺结节的强化特征,探讨造影增强超声检查甲状腺结节的可行性。方法对49例孤立性甲状腺结节患者行造影增强超声检查,利用造影增强超声后处理软件定量测量注射造影剂后甲状腺结节内部感兴趣区(ROI)和病灶外正常甲状腺实质ROI的回声强度。比较注射造影剂后不同时间良恶性结节及病灶外正常甲状腺实质ROI的回声强度值,采用SNK检验进行统计学分析。结果注射造影剂后25s和60s良性结节回声强度均高于恶性结节和正常甲状腺实质(P<0.05)。结论造影增强超声检查定性诊断甲状腺结节是可行的,良性结节的强化幅度显著高于恶性结节。
作者 刘波泉
出处 《南方医科大学学报》 CAS CSCD 北大核心 2008年第11期2107-2108,共2页 Journal of Southern Medical University
  • 相关文献

参考文献6

  • 1Argalia G, De Bemardis S, Mariani D, et al. Ultrasonographic contrast agent: evaluation of time-intensity curves in the charaeterisation of solitary thyroid nodules [J]. Radiol Med (Torino), 2002, 103(4): 407-13.
  • 2侯振亚,曹崑,唐光健,王霄英,蒋学祥.增强CT对甲状腺局灶性病变良恶性鉴别的评价[J].中国医学影像技术,2006,22(6):850-853. 被引量:29
  • 3肖雁冰,王智彪,李发琪.SonoVue在超声诊断中的应用[J].临床超声医学杂志,2004,6(4):239-241. 被引量:9
  • 4Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion [J]. Circulation, 1998, 97(5): 473-83.
  • 5李奇林,全学模.超声微泡造影剂的临床应用及研究进展[J].国外医学(临床放射学分册),2006,29(6):419-421. 被引量:2
  • 6Bartolotta TV, Midiri M, Galia M, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: initial results [ J ]. Eur Radiol, 2006, 16(10): 2234-41.

二级参考文献61

  • 1刘铁,董吉顺,张亮亮,卞纪平,叶林生.甲状腺肿瘤CT-病理对照研究[J].中华放射学杂志,1995,29(11):765-768. 被引量:78
  • 2""Senior R, Andersson O, Caidahl K, et al. Enhanced left ventricular endocardial border delineation with an intravenous injection of SonoVue, a new echocardiographic contrast agent: A European multicenter study. Echocardiography, 2000 ,17(8): 705~711.
  • 3""Leen E, Angerson WJ, Yarmenitis S, et al. Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol, 2002, 41(3): 200~206.
  • 4""Basilico R, BlomLey MJ, Harvey CJ, et al. Which continuous US scanning mode is optimal for the detection of vascularity in liver lesions when enhanced with a second generation contrast agent. Eur J Radiol, 2002 , 41(3): 184~191.
  • 5Bokor D, Chambers JB, Rees PJ, et al. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest Radiol, 2001, 36(2): 104~109.
  • 6""Hohmann J, Skrok J, Puls R, et al. Characterization of focal liver lesions with contrast-enhanced low MI real time ultrasound and SonoVue. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr, 2003 ,175(6): 835~843.
  • 7Lafitte S, Higashiyama A, Masugata H, et al. Contrast echocardiography can assess risk area and infarct size during coronary occlusion and reperfusion: experimental validation. J Am Coll Cardiol,2002,39(9):1 546~1 554.
  • 8Alexander L. (Sasha) Klibanov. Targeted delivery of gas-filled microsp-heres, contrast agents for ultrasound imaging[J]. Advanced Drug Delivery Reviews,1999, 37: 139-157.
  • 9Nahar T, Li P, Kuersten B, et al. Detection of resting myocardial perfusion defects by SonoVue myocardial contrast echocardiography. Echocardiography, 2003, 20(6): 511-517.
  • 10Broillet A, Puginier J, Ventrone R, et al. Assessment of myocardial perfusion by intermittent harmonic power Doppler using SonoVue, a new ultrasound contrast agent. Invest Radiol, 1998 ,33(4): 209-215.

共引文献37

同被引文献94

引证文献9

二级引证文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部